OTCMKTS:SGIOY Shionogi & Co., Ltd. (SGIOY) Stock Price, News & Analysis $7.59 -0.07 (-0.91%) As of 03/28/2025 03:50 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestBuy This Stock About Shionogi & Co., Ltd. Stock (OTCMKTS:SGIOY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Shionogi & Co., Ltd. alerts:Sign Up Key Stats Today's Range$7.50▼$7.8050-Day Range$6.78▼$7.7852-Week Range$6.22▼$8.59Volume44,701 shsAverage Volume134,492 shsMarket Capitalization$12.91 billionP/E Ratio13.06Dividend Yield1.45%Price TargetN/AConsensus RatingN/A Company OverviewShionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a COVID-19 prophylactic vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for COVID-19 treatment and prevention; baloxavir for influenza virus infection; S-365598 for HIV infection; and S-555739 for suppressing aggravation of COVID-19. In addition, the company develops S-540956 for nucleic acid adjuvant; S-109802 for post-stroke spasticity; S-151128 for chronic pain; S-588210 and S-531011 for solid tumor; S-309309 for obesity; BPN14770 for Alzheimer's disease and fragile X syndrome; S-588410 for bladder cancer; S-488210 for head and neck squamous cell carcinoma; S-005151 for Acute ischemic stroke and epidermolysis bullosa; Rizmoic for opioid-induced constipation; ADR-001 for decompensated liver cirrhosis; S-222611 for malignant tumor; S-812217 for depression; GRT7039 for pain associated with osteoarthritis of the knee; SDT-001 for inattentive ADHD; S-588410 for esophageal cancer; SR-0379 for cutaneous ulcer; and S-723595 for type 2 diabetes. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.Read More… Remove Ads Shionogi & Co., Ltd. Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks22nd Percentile Overall ScoreSGIOY MarketRank™: Shionogi & Co., Ltd. scored higher than 22% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Shionogi & Co., Ltd.. Earnings and Valuation1.3 / 5Proj. Earnings Growth-1.52% Earnings GrowthEarnings for Shionogi & Co., Ltd. are expected to decrease by -1.52% in the coming year, from $0.66 to $0.65 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Shionogi & Co., Ltd. is 13.06, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 22.58.Price to Earnings Ratio vs. SectorThe P/E ratio of Shionogi & Co., Ltd. is 13.06, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 23.60.Price to Earnings Growth RatioShionogi & Co., Ltd. has a PEG Ratio of 2.37. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioShionogi & Co., Ltd. has a P/B Ratio of 1.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Shionogi & Co., Ltd.'s valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.00% of the float of Shionogi & Co., Ltd. has been sold short.Short Interest Ratio / Days to CoverShionogi & Co., Ltd. has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Shionogi & Co., Ltd. has recently increased by 58.56%, indicating that investor sentiment is decreasing significantly. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldShionogi & Co., Ltd. pays a meaningful dividend of 1.47%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthShionogi & Co., Ltd. does not have a long track record of dividend growth.Dividend SustainabilityBased on earnings estimates, Shionogi & Co., Ltd. will have a dividend payout ratio of 16.92% next year. This indicates that Shionogi & Co., Ltd. will be able to sustain or increase its dividend.Read more about Shionogi & Co., Ltd.'s dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.00% of the float of Shionogi & Co., Ltd. has been sold short.Short Interest Ratio / Days to CoverShionogi & Co., Ltd. has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Shionogi & Co., Ltd. has recently increased by 58.56%, indicating that investor sentiment is decreasing significantly. News and Social Media1.9 / 5News SentimentN/A News SentimentShionogi & Co., Ltd. has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.81 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Shionogi & Co., Ltd. this week, compared to 0 articles on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Shionogi & Co., Ltd. insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 1.92% of the stock of Shionogi & Co., Ltd. is held by institutions.Read more about Shionogi & Co., Ltd.'s insider trading history. Receive SGIOY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Shionogi & Co., Ltd. and its competitors with MarketBeat's FREE daily newsletter. Email Address SGIOY Stock News HeadlinesShionogi’s Ensitrelvir Shows Promise in COVID-19 PreventionMarch 12, 2025 | tipranks.comShionogi targets JPY550B revenue through QOL focus and global expansionFebruary 1, 2025 | msn.comNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. March 30, 2025 | Porter & Company (Ad)Shionogi & Co., Ltd. (SGIOY) Q3 2024 Earnings Call TranscriptJanuary 31, 2025 | seekingalpha.comShionogi & Co. (SGIOY) Upgraded to Buy: What Does It Mean for the Stock?January 27, 2025 | msn.comShionogi awarded $375m from HHS for preventative Covid-19 injectableJanuary 17, 2025 | finance.yahoo.comShionogi Receives Award Through BARDA's Rapid Response Partnership Vehicle to Advance Long-Acting Formulation of S-892216, an Antiviral for COVID-19 Pre-Exposure Prophylaxis in ...January 16, 2025 | businesswire.comNxera Pharma and Shionogi Launch QUVIVIQ(TM) in Japan for Adults with InsomniaDecember 19, 2024 | stockhouse.comSee More Headlines SGIOY Stock Analysis - Frequently Asked Questions How have SGIOY shares performed this year? Shionogi & Co., Ltd.'s stock was trading at $6.9599 at the beginning of 2025. Since then, SGIOY stock has increased by 9.1% and is now trading at $7.59. View the best growth stocks for 2025 here. How were Shionogi & Co., Ltd.'s earnings last quarter? Shionogi & Co., Ltd. (OTCMKTS:SGIOY) issued its quarterly earnings data on Friday, January, 31st. The company reported $0.16 EPS for the quarter. Shionogi & Co., Ltd. had a net margin of 35.53% and a trailing twelve-month return on equity of 12.02%. How do I buy shares of Shionogi & Co., Ltd.? Shares of SGIOY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings1/31/2025Today3/30/2025Fiscal Year End3/31/2025Next Earnings (Estimated)5/12/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Private households Sub-IndustryPersonal Services Current SymbolOTCMKTS:SGIOY CIK1281721 Webwww.shionogi.co.jp Phone(166) 202-2161FaxN/AEmployees5,690Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio13.06 Forward P/E Ratio11.50 P/E Growth2.37Net Income$1.12 billion Net Margins35.53% Pretax MarginN/A Return on Equity12.02% Return on Assets10.64% Debt Debt-to-Equity Ratio0.01 Current Ratio7.64 Quick Ratio7.01 Sales & Book Value Annual Sales$3.01 billion Price / Sales4.28 Cash Flow$0.73 per share Price / Cash Flow10.34 Book Value$5.29 per share Price / Book1.43Miscellaneous Outstanding Shares1,701,379,000Free FloatN/AMarket Cap$12.91 billion OptionableNot Optionable Beta0.23 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (OTCMKTS:SGIOY) was last updated on 3/30/2025 by MarketBeat.com Staff From Our PartnersTrump’s Great Society Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredElon’s ‘Strike Squad’ sends these 9 stocks soaring?Elon Musk's DOGE 'strike squad' just revealed it's speeding up the rollout of a radical technology across the ...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Shionogi & Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Shionogi & Co., Ltd. With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.